Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis

Chen, Bin; Sun, Donghong; Qin, Xiuni; Gao, Xing‐Hua

doi:10.1007/s10637-021-01072-y

Cited by 4 publications

(3 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with other Sema4 proteins, Sema4D has been more studied in tumors (Table 1). Sema4D was found to be highly expressed in ovarian cancer [80], lung cancer [81], colon cancer [82,83], bladder cancer [84], invasive head and neck squamous cell carcinoma (HNSCC) [85], sarcoma [86,87], melanoma [88], metastatic cervical cancer [89]. Its expression levels were correlated with the pathology and prognosis of patients [80-83, 87, 89].…”

Section: Sema4dmentioning

confidence: 99%

Dongjun Jiang, Xiaoli Chen, Xiuting Li, Jian Qiu, Peng Xu, Xuezhi Li

and

2024

neo

View full text Add to dashboard Cite

Semaphorins are originally described as regulators of nervous system development. Besides, members of the semaphorin family play important roles in the growth, metastasis, and angiogenesis of solid tumors. In contrast to the other semaphorin subclasses, semaphorin class 4 has both membrane-bound and active soluble forms. Soluble class 4 semaphorins in body fluids (blood and saliva) may serve as potential biomarkers for early diagnosis and prognosis prediction of specific cancers. The class 4 semaphorins also transduce signal in cancer cells in a cell membrane-bound form, thereby regulating cancer progression. In solid tumors, class 4 semaphorins can act as ligands in active soluble forms, regulating cancer progression via autocrine and paracrine to activate signal transduction in cancer cells or endothelial cells in the tumor microenvironment. Targeting class 4 semaphorins may be a novel strategy for specific cancer therapy. However, the expression of class 4 semaphorins in solid tumors and the responsive pathogenesis are still controversial. Therefore, this review summarizes the specific expression regulation of class 4 semaphorin members in different types of solid tumors and the mechanisms involved in cancer progression.

show abstract

Section: Sema4dmentioning

confidence: 99%

Dongjun Jiang, Xiaoli Chen, Xiuting Li, Jian Qiu, Peng Xu, Xuezhi Li

and

2024

neo

View full text Add to dashboard Cite

show abstract

“…Melanoma is a malignancy that develops from the uncontrolled proliferation of melanocytes. Melanoma is a highly invasive malignant tumour with a high rate of metastasis and death, and prevalence has been growing (Chen et al., 2021 ). The development of melanoma has been attributed to multiple factors, with ultraviolet light recognized as one of the most common risk factors, as well as gene mutations (Ferguson, 2021 , Lopes et al., 2021 ).…”

Section: Ti‐evs In Multiple Cancersmentioning

confidence: 99%

Tissue‐derived extracellular vesicles in cancers and non‐cancer diseases: Present and future

Man

Gao

et al. 2021

J of Extracellular Vesicle

109

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are lipid‐bilayer membrane structures secreted by most cell types. EVs act as messengers via the horizontal transfer of lipids, proteins, and nucleic acids, and influence various pathophysiological processes in both parent and recipient cells. Compared to EVs obtained from body fluids or cell culture supernatants, EVs isolated directly from tissues possess a number of advantages, including tissue specificity, accurate reflection of tissue microenvironment, etc., thus, attention should be paid to tissue‐derived EVs (Ti‐EVs). Ti‐EVs are present in the interstitium of tissues and play pivotal roles in intercellular communication. Moreover, Ti‐EVs provide an excellent snapshot of interactions among various cell types with a common histological background. Thus, Ti‐EVs may be used to gain insights into the development and progression of diseases. To date, extensive investigations have focused on the role of body fluid‐derived EVs or cell culture‐derived EVs; however, the number of studies on Ti‐EVs remains insufficient. Herein, we summarize the latest advances in Ti‐EVs for cancers and non‐cancer diseases. We propose the future application of Ti‐EVs in basic research and clinical practice. Workflows for Ti‐EV isolation and characterization between cancers and non‐cancer diseases are reviewed and compared. Moreover, we discuss current issues associated with Ti‐EVs and provide potential directions.

show abstract

“…GO analysis is often used for functional enrichment research in the three aspects of biological processes (BPs), molecular functions (MFs) and cellular component (CCs) (15). The pathways were analyzed using KEGG pathway enrichment (16). Subsequently, GO and KEGG analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID version 6.8) tools (https://david.ncifcrf.gov/).…”

Section: Analysis Of Gene Ontology (Go) Function and Kyotomentioning

confidence: 99%

Anti‑malarial drug dihydroartemisinin downregulates the expression levels of CDK1 and CCNB1 in liver cancer

Hao

Peng

et al. 2021

Oncol Lett

View full text Add to dashboard Cite

Liver cancer is the third leading cause of cancerassociated mortality worldwide. By the time liver cancer is diagnosed, it is already in the advanced stage. Therefore, novel therapeutic strategies need to be identified to improve the prognosis of patients with liver cancer. In the present study, the profiles of GSE84402, GSE19665 and GSE121248 were used to screen differentially expressed genes (DEGs).

show abstract

Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis

Cited by 4 publications

References 123 publications

Dongjun Jiang, Xiaoli Chen, Xiuting Li, Jian Qiu, Peng Xu, Xuezhi Li

Dongjun Jiang, Xiaoli Chen, Xiuting Li, Jian Qiu, Peng Xu, Xuezhi Li

Tissue‐derived extracellular vesicles in cancers and non‐cancer diseases: Present and future

Anti‑malarial drug dihydroartemisinin downregulates the expression levels of CDK1 and CCNB1 in liver cancer

Contact Info

Product

Resources

About